Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe

Abstract

BackgroundIt has been described that treating relapsing–remitting multiple sclerosis (RRMS) patients with alemtuzumab following fingolimod could be less effective due to the different dynamics of lymphocyte repopulation. Effectiveness and safety of alemtuzumab compared to rituximab after fingolimod withdrawal were analyzed.Patients and methodsA follow-up of a cohort of RRMS patients treated with alemtuzumab or rituximab after fingolimod withdrawal was accomplished. Effectiveness, measured by the percentage of patients with no evidence of disease activity (NEDA), and the presence of side effects (SE) were registered.ResultsFifty-five patients, 28 with alemtuzumab and 27 with rituximab, were analyzed. No differences in the washout period or in the baseline lymphocytes counts were observed. After a mean follow-up period of 28.8\xa0months, the annualized relapsing rate was significantly reduced in the alemtuzumab group from 1.29 to 0.004 (p\u2009<\u20090.001) and in the rituximab group from 1.24 to 0.02 (p\u2009<\u20090.001), without differences. A significant reduction of the median EDSS from 2.8 to 2.0 in the alemtuzumab group and from 3.5 to 2.5 (p\u2009<\u20090.01) in the rituximab group was observed, without differences. Eighty-two per cent (n\u2009=\u200928) of patients in alemtuzumab group and 69.2% (n\u2009=\u200926) in rituximab group achieved NEDA criteria, without differences (p\u2009=\u20090.3). Symptoms related to the infusion were the most frequent SE in both groups. No serious SE were registered.ConclusionTreating RRMS patients with alemtuzumab or rituximab after fingolimod withdrawal is effective and safe, without significant differences between both groups in our series.